Source-grounded facts extracted from Certara, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Faiz Mohammed was appointed as Interim Chief Financial Officer at Certara, Inc..
“On June 17, 2026, the Company appointed Faiz Mohammed as its Interim Chief Financial Officer and as both principal financial officer and principal accounting officer of the Company for purposes of the Securities Exchange Act of 1934, as amended, effective as of the Effective Date and until a successor may be appointed.”
John E. Gallagher III resigned as Chief Financial Officer at Certara, Inc..
“On June 11, 2026, John E. Gallagher III, Senior Vice President and Chief Financial Officer of Certara, Inc. (the “Company”), tendered his notice of resignation to the Company to pursue another opportunity.”
Certara, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-14 meeting.
“The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for the most recently completed fiscal year. The voting results were as follows: For Against Abstain Broker Non-Vote 120,333,107 2,289,297 113,268 19,881,657”
Certara, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for 2026 fiscal year at the 2026-05-14 meeting.
“The Company’s stockholders ratified the selection of RSM US LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. The voting results were as follows: For Against Abstain Broker Non-Vote 141,730,429 764,353 122,547 0”
Certara, Inc. shareholders approved Election of three Class III directors at the 2026-05-14 meeting.
“The Company’s stockholders elected the three Class III directors listed below to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified. The voting results were as follows: For Withheld Broker Non-Vote Arjun Bedi 121,707,485 1,028,187 19,881,657 Stephen McLean 99,884,645 22,851,027 19,881,657 Jon Resnick 121,713,279 1,022,393 19,881,657”
Certara, Inc. reported the three-month period ended March 31, 2026 results: revenue $106.9 million, net income Net loss was $8.8 million, EPS Diluted loss per share of $0.06. Guidance lowered.
“First Quarter 2026 Results Total revenue for the first quarter of 2026 was $106.9 million, representing year-over-year growth of 1% on a reported basis. Software revenue for the first quarter of 2026 was $49.7 million, representing year-over-year growth of 7% on a reported basis. Services revenue for the first quarter of 2026 was $57.2 million, representing a year-over-year decrease of 4% on a reported basis . Total Bookings for the first quarter of 2026 were $115.3 million, representing a year-over-year decrease of 2%. Software Bookings for the first quarter of 2026 were $48.7 million, representing a year-over-year increase of 20%. The increase in software bookings was attributable to strong customer demand across our platform. Services Bookings for the first quarter of 2026 were $66.6 million, representing a year-over-year decrease of 14%. The decrease in services bookings was primarily driven by the timing of contract recognition and execution. Total cost of revenues for the first q”
Certara, Inc. entered into Purchase Agreement with Veristat, LLC and certain of its affiliates valued at $100 million (effective 2026-04-21).
“On April 21, 2026, Certara, Inc. (the “Company”), together with certain of its subsidiaries, entered into a Purchase Agreement (the “Purchase Agreement”) with Veristat, LLC and certain of its affiliates (collectively, “Veristat”), pursuant to which the Company agreed to sell its global medical writing and related regulatory services business (the “Business”) to Veristat.”
Certara, Inc. incurred term loan with Bank of America, N.A., as administrative agent for the Lenders and collateral agent for the secured parties thereunder at Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 2.75%.
“The Replacement Term Loans were funded in full on the Closing Date and were applied by the Company to refinance the Existing Term Loans (as defined in the Amendment) previously outstanding under the Credit Agreement.”
Certara, Inc. amended credit facility with Bank of America, N.A., as administrative agent for the Lenders and collateral agent for the secured parties thereunder at Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 2.75%.
“The Amendment provides for, among other things, a reduction in the Applicable Rate (as defined in the Credit Agreement) with respect to the term loans under the Credit Agreement, which is expected to reduce the Company’s cost of borrowing and allow for interest expense savings, as compared to prior terms under the Credit Agreement.”
Dr. Patrick F. Smith departed as President, Certara Drug Development Solutions at Certara, Inc..
“On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advisory and scientific role.”
Dr. John V. W. Reynders was appointed as Class II director at Certara, Inc..
“On October 16, 2024, the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Dr. John V. W. Reynders as a Class II director of the Board and a member of the Audit Committee of the Board, effective immediately.”
Certara, Inc. reported the first quarter of fiscal year 2024 results: revenue $96.7 million, net income Net loss was $4.7 million. Guidance reaffirmed.
“Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: • Revenue was $96.7 million, compared to $90.3 million in the first quarter of 2023, representing growth of 7%. • Software revenue was $39.3 million , compared to $33.0 million in the first quarter of 2023”
Certara, Inc. reported the fourth quarter of fiscal year 2023 results: revenue $88.0 million, net income Net loss was $12.5 million. Guidance initiated.
“Certara Reports Fourth Quarter 2023 Financial Results Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: • Revenue was $88.0 million, compared to $86.6 million in the fourth quarter of 2022, representing growth of 2% over the fourth quarter of 2022. • Strong sequential growth with record software bookings and broad-based recovery in technology enabled services bookings during the quarter. • Net loss was $12.5 million, compared to a net income of $9.2 million in the fourth quarter of 2022.”
Certara, Inc. updated its third quarter of fiscal year 2023 guidance (reaffirmed).
“On November 8, 2023 , Certara, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended September 30, 2023.”
Certara, Inc. reported the second quarter of fiscal year 2023 results: revenue $90.5 million, net income $4.7 million. Guidance reaffirmed.
“Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: • Revenue was $90.5 million, compared to $82.8 million in the second quarter of 2022, representing growth of 9% over the second quarter of 2022 on a reported basis and 10% at constant currency. • Net income”
Certara, Inc. shareholders approved Election of three Class III directors at the 2023-05-23 meeting.
“On May 23, 2023, Certara, Inc. (the “Company”) held its annual meeting of shareholders.”
Certara, Inc. reported first quarter of fiscal year 2023 results: revenue $90.3 million, net income $1.4 million. Guidance reaffirmed.
“financial and strategic objectives and look forward to continued success in 2023,” said John Gallagher, Chief Financial Officer. Total revenue for the first quarter of 2023 was $ 90.3 million , representing growth of 11% over the first quarter of 2022. The overall increase in revenue was primarily due to growth in our technology-driven services and software product”
M. Andrew Schemick changed role as Chief Financial Officer at Certara, Inc..
“M. Andrew Schemick, the Company’s current Chief Financial Officer, who will be stepping down from that role at the end of the day on March 31, 2023, but will remain with the Company in a senior executive role.”
John E. Gallagher III was appointed as Chief Financial Officer at Certara, Inc..
“John E. Gallagher III has been appointed as the Company’s Chief Financial Officer, effective April 1, 2023.”
Mason Slaine resigned as Director at Certara, Inc..
“On December 23, 2022, Mr. Mason Slaine, a member of the Board of Directors of Certara, Inc. (the “Company”), and a member of the Nominating and Corporate Governance Committee notified the Company of his intention to resign as a director of the Company for personal reasons, effective December 23, 2022.”
David Spaight was appointed as Director at Certara, Inc..
“Also on December 8, 2022, David Spaight was appointed to the Board, effective upon the closing, as a Class I director with a term expiring at the Company’s 2024 Annual Meeting of Shareholders, and Mr. Spaight was appointed to serve as a member of the Board’s Compensation Committee, effective upon the closing.”
Ethan Waxman resigned as Director at Certara, Inc..
“On December 8, 2022, in connection with the closing of the Sale Transaction (as defined below) (the “closing”), Eric Liu and Ethan Waxman, each a member of the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), each notified the Company of his decision to resign as a director of the Company, effective upon the closing.”
Eric Liu resigned as Director at Certara, Inc..
“On December 8, 2022, in connection with the closing of the Sale Transaction (as defined below) (the “closing”), Eric Liu and Ethan Waxman, each a member of the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), each notified the Company of his decision to resign as a director of the Company, effective upon the closing.”
Certara, Inc. entered into Stockholders Agreement with Arsenal Capital Partners (affiliate) (effective 2022-11-03).
“The Company entered into a Stockholders Agreement, dated as of November 3, 2022 (the “Stockholders Agreement”), with Arsenal.”
Certara, Inc. entered into Letter Agreement with Arsenal Capital Partners (affiliate) (effective 2022-11-03).
“The Company entered into a letter agreement, dated as of November 3, 2022 (the “Letter Agreement”), with Arsenal providing that, until the two-year anniversary of the closing, Arsenal will, subject to certain exceptions, be prohibited from transferring the shares of Common Stock that it will acquire in connection with the closing.”
Certara, Inc. reported third quarter of fiscal year 2022 results: revenue $84.7 million, net income $3.9 million. Guidance reaffirmed.
“in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance. Third Quarter Highlights: ● Revenue was $84.7 million, compared to $73.9 million in the third quarter of 2021, representing growth of 15% over the third quarter of 2021 on a reported basis and 18% at constant currency. ● Net income”
David Spaight was appointed as Director at Certara, Inc..
“Arsenal intends to nominate David Spaight to the Board following the closing and the departure of Mssrs. Liu and Waxman from the Board.”
Ethan Waxman departed as Director at Certara, Inc..
“Eric Liu and Ethan Waxman are each expected to resign from the Board following the closing.”
Eric Liu departed as Director at Certara, Inc..
“Eric Liu and Ethan Waxman are each expected to resign from the Board following the closing.”
Justin Edge resigned as President of Regulatory and Access at Certara, Inc..
“On August 12, 2022, Certara, Inc (the “Company”) announced the resignation from the Company of Justin Edge, President of Regulatory and Access.”
Rosemary A. Crane was elected as Class III director at Certara, Inc..
“On July 21, 2022, the Board elected Rosemary A. Crane, as a Class III director, effective July 21, 2022.”
Eran Broshy was elected as Class III director at Certara, Inc..
“On July 11, 2022, the Board elected Eran Broshy, as a Class III director, effective July 11, 2022.”
Carol Gallagher resigned as Director at Certara, Inc..
“On April 5, 2022, Dr. Carol Gallagher, a member of the Board of Directors of Certara, Inc. (the “Company”), Chair of the Compensation Committee, and member of the Nominating and Corporate Governance Committee notified the Company of her intention to resign as a director of the Company for personal reasons, effective April 5, 2022.”
Nancy Killefer was elected as Class III director at Certara, Inc..
“Nancy Killefer as a Class III director”
Cynthia Collins was elected as Class II director at Certara, Inc..
“the Board elected Cynthia Collins as a Class II director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.